文献速递生殖医学

SWS1复合物在早发性卵巢功能不全中的作用:SWSAP1为新发现的POI基因

SWS1-complex in premature ovarian insufficiency: SWSAP1 as a new POI gene.
PubMed 文献 · Hum Reprod · 2025-01-01

该研究通过对5例法国早发性卵巢功能不全(POI)患者进行外显子或基因组测序,在SWS1复合物基因SWS1/ZSWIM7和SWSAP1中鉴定出5个致病或可能致病变异,其中SWSAP1 c.353del为纯合移码缺失。功能实验显示这些变异导致同源重组间质同源重组(IH-HR)活性部分降低或缺失,患者均表现为严重孤立性POI伴原发性或早期继发性闭经及青春期延迟迹象。

要点

  • 在5例POI患者中鉴定出SWS1/ZSWIM7和SWSAP1的5个致病或可能致病变异。
  • SWSAP1 c.353del纯合移码缺失为首次在女性不育中报道的SWSAP1变异。
  • IH-HR实验可作为验证POI患者同源重组基因新变异的功能学方法。

核心结论

  • SWS1复合物三个成员均参与女性生育力,SWSAP1为新发现的POI基因。

研究设计与样本

  • 对5例来自法国的无亲缘关系POI患者进行外显子或基因组测序筛查SWS1复合物变异,并进行计算机建模、IH-HR实验和蛋白质印迹分析。

主要发现

  • 5例患者携带5个不同的致病或可能致病变异:SWS1/ZSWIM7的c.231_232del和c.176C>T(既往报道),c.22del和c.151C>T(新发现),以及SWSAP1的c.353del纯合移码缺失。
  • 所有患者均表现为严重孤立性POI,伴原发性或早期继发性闭经及青春期延迟迹象。
  • 计算机建模和IH-HR实验显示SWS1/ZSWIM7 c.176C>T和SWSAP1 c.353del分别导致Sws1-/-或Swsap1-/-细胞中IH-HR活性部分降低或缺失,并导致SWSAP1截短突变体不稳定。

临床怎么用

  • 作者认为IH-HR实验可为POI患者同源重组基因的新变异提供相关的功能验证方法。

局限性

  • 需要鉴定其他携带SWSAP1变异的患者以深入评估表型与基因型的相关性。
  • 未来研究应评估SWS1复合物中其他基因的作用,并探索靶向同源重组的治疗干预潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What other zinc finger SWIM domain-containing protein 7 (SWS1/ZSWIM7) partners are involved in premature ovarian insufficiency (POI)? SUMMARY ANSWER: This study identifies novel pathogenic variants in zinc finger SWIM domain-containing protein 7 (SWS1/ZSWIM7) and its partner, SWSAP1, which impair interhomolog homologous recombination (IH-HR) and lead to isolated POI. WHAT IS KNOWN ALREADY: Knockout mice models of the SWS1-complex (also known as the SWS1-SWSAP1-SPIDR complex or Shu complex) are infertile due to meiotic arrest. Variants of both SWS1/ZSWIM7 and SPIDR are described in POI, but so far, no SWSAP1 variants have been described in female infertility. STUDY DESIGN, SIZE, DURATION: Screening for SWS1-complex variants was performed using exome or genome sequencing data from women with POI as ongoing patient care. In silico modelling, IH-HR assays, and western-blot analysis were performed to test the impact of novel variants identified in genes of the SWS1-complex (SWSAP1 and SWS1/ZSWIM7) on homologous recombination, protein expression, and protein interactions. PARTICIPANTS/MATERIALS, SETTING, METHODS: Five unrelated patients from France were enrolled based on their exome or genome sequencing result as part of ongoing patient care. All the patients were diagnosed with POI and met the European Society of Human Reproduction and Embryology (ESHRE) diagnostic criteria for POI. Functional validation was performed using mouse embryonic stem cells to study the impact of two novel variants found in two patients. MAIN RESULTS AND THE ROLE OF CHANCE: We report five different pathogenic or likely pathogenic variants in five patients. We report the previously described c.231_232del and c.176C>T variants in SWS1/ZSWIM7, as well as two novel variants, c.22del and c.151C>T. Additionally, we report a homozygous frameshift deletion in SWSAP1 (c.353del). All the patients display a similar phenotype of severe isolated POI, associated with primary or early secondary amenorrhea and signs of puberty delay. In silico modelling and IH-HR assays of both SWS1/ZSWIM7 c.176C>T and SWSAP1 c.353del indicated a partial decrease or absence of IH-HR activity in Sws1-/- or Swsap1-/- cells, respectively, and destabilization of the SWSAP1 truncation mutant. LIMITATIONS, REASONS FOR CAUTION: Identification of other patients carrying SWSAP1 variants is needed to evaluate in-depth phenotype to genotype correlations. Future studies should evaluate the role of other genes in the SWS1-complex and explore the potential for therapeutic interventions targeting homologous recombination. WIDER IMPLICATIONS OF THE FINDINGS: These findings provide direct clinical and functional evidence that all three members of the SWS1-complex are implicated in female fertility and recapitulate the observed mouse phenotypes. IH-HR assays provide a relevant functional approach to validate novel variants in homologous recombination genes for POI patients, given the importance of IH-HR for meiotic progression. STUDY FUNDING/COMPETING INTEREST(S): The French Genomic Medicine Initiative PFMG2025 is supported by grants from the French government, notably by the French National Research Agency under the Programme d'Investissments d'Avenir for the CAD (ANR-21-ESRE0001) and the CRefIX (ANR-10-INBS-09-01). M.J. was supported by R01 HD112624 and R35CA253174 grants. E.J.T. was supported by a Norman Beischer Fellowship and a Centre for Research Excellence for Women's Health in Reproductive Life (CRE-WHiRL) fellowship from the National Health and Medical Research Council (NHMRC). J.F.M. was supported by a Research Training Program scholarship from the Australian Government. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: This manuscript included genomic analysis performed in clinical practice in patients with RD/CGP and cancers in France. Consequently, a clinical trial NCT number was not required as we reported in this manuscript results obtained in clinical practice. In compliance with the French law on bioethics (2004-800, 06/08/2004), patients had signed written informed consent forms for clinical practice and had been informed of the research use of what remained of their samples after establishing the molecular diagnosis.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Lokchine A, Zhang F, Cluzeau L, et al. SWS1-complex in premature ovarian insufficiency: SWSAP1 as a new POI gene. Hum Reprod. 2025. PMID: 40991243. doi:10.1093/humrep/deaf177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。